책 이미지
eBook 미리보기
책 정보
· 제목 : The EBMT/EHA CAR-T Cell Handbook (Paperback)
· 분류 : 외국도서 > 의학 > 간호학 > 간호학 일반
· ISBN : 9783030943523
· 쪽수 : 237쪽
· 출판일 : 2022-02-08
· 분류 : 외국도서 > 의학 > 간호학 > 간호학 일반
· ISBN : 9783030943523
· 쪽수 : 237쪽
· 출판일 : 2022-02-08
목차
1. Introduction
N Kroger, J Gribben, C Chabannon, H Einsele, I Yakoub-Agha
2. The science behind CAR-T Cells
J Gribben.
2. Structure of and signaling through the Chimeric Antigen Receptor
3. Genetic engineering of autologous or allogeneic immune effector cells
4. What defines a good tumor antigen? Minimizing or managing on target / off tumor and off target / off tumor effects
5. Mechanisms of resistance to CAR-T
6. The European landscape for preclinical and early clinical research
Chapter 3. Manufacturing CAR-T Cells: the supply chain.
C Chabannon.
7. Providing the starting material to the manufacturer of an approved and commercially available autologous CAR-T Cell treatment
8. Receiving, handling, storage, distribution, thawing and administration of the Gene Therapy Medicinal Product (GTMP) shipped from the manufacturing facility
9. Point-of-Care (POC) manufacturing of autologous CAR-T Cells
10. Off-the shelf allogeneic CAR-T Cells or other Immune Effector Cells (IECs) for the future
4. Clinical indications for CAR-T Cells.
H Einsele.
11. Pediatric Acute Lymphoblastic Leukemia (ALL)
12. Adult Acute Lymphoblastic Leukemia (ALL)
13. Diffuse Large B Cell Lymphoma and Primary Mediastinal Lymphoma
14. Mantle Cell Lymphoma
15. Chronic Lymphocytic Leukemia
16 Indolent lymphomas
17. Multiple Myeloma
18. Developments in other hematological malignancies
i. Other lymphoid malignancies
ii. Myeloid Malignancies
i. Developments in solid tumors
5. Clinical management of patients treated with CAR-T Cells.
I Yakoub-Agha.
19. Bridging chemotherapy/ general chapter
i. Adult ALL
ii. Pediatric and young adult ALL
iii. DLBCL, FL and indolent lymphomas
iv. Multiple myeloma
20. Lymphodepleting Conditioning Regimens
21. Management of Cytokine Release Syndrome (CRS)
22. Management of Immune effector Cells Associated Neurotoxicity Syndrome (ICANS)
23. Management of hypogammaglobulinemia and B-cell aplasia
24. Management of myelotoxicity(aplasia) and infectious complications
25. Management of other toxicities 26. ICU
i. Post CAR-T cell therapy (consolidation and relapse)
i. ALL
ii. Lymphomas
iii. MM
27. Immune monitoring
28. Long-term follow-up and late effects
6. Access to CAR-T cells.
N Kroger
29. The regulatory framework for CAR-T cells in Europe: current status and foreseeable changes
30. Center qualification by competent authorities and manufacturers
31. How can accreditation bodies such as JACIE or FACT support centers in getting qualified? 32 Educational needs for physicians
33. Educational needs for nurses
34 Educational needs for pharmacists
25. Educational needs for Cell Collection and Cell Processing Facility personnel
36. GoCART project
37. Patient referral
38 Treatment coverage and reimbursement
39. Assessing the medical value of CAR-T Cells
40 What do patients want? The importance of patient reported outcome
![[eBook Code] Molecular Hematology (eBook Code, 4th)](/img_thumb2/9781119252931.jpg)
![[eBook Code] Molecular Hematology (eBook Code, 4th)](/img_thumb2/9781119252955.jpg)
